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Background: Chronic kidney disease (CKD) is one of the most serious public health problems. The increasing
prevalence of CKD in developed and developing countries has led to a global epidemic. The hypothesis proposed
is that patients undergoing dialysis would experience a marked negative influence on physiological variables of
sleep and autonomic nervous system activity, compromising quality of life.
Methods/Design: A prospective, consecutive, double blind, randomized controlled clinical trial is proposed to
address the effect of dialysis on sleep, pulmonary function, respiratory mechanics, upper airway collapsibility,
autonomic nervous activity, depression, anxiety, stress and quality of life in patients with CKD. The measurement
protocol will include body weight (kg); height (cm); body mass index calculated as weight/height2; circumferences
(cm) of the neck, waist, and hip; heart and respiratory rates; blood pressures; Mallampati index; tonsil index; heart
rate variability; maximum ventilatory pressures; negative expiratory pressure test, and polysomnography (sleep
study), as well as the administration of specific questionnaires addressing sleep apnea, excessive daytime sleepiness,
depression, anxiety, stress, and quality of life.
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Discussion: CKD is a major public health problem worldwide, and its incidence has increased in part by the
increased life expectancy and increasing number of cases of diabetes mellitus and hypertension. Sleep disorders are
common in patients with renal insufficiency. Our hypothesis is that the weather weight gain due to volume
overload observed during interdialytic period will influence the degree of collapsibility of the upper airway due to
narrowing and predispose to upper airway occlusion during sleep, and to investigate the negative influences of
haemodialysis in the physiological variables of sleep, and autonomic nervous system, and respiratory mechanics
and thereby compromise the quality of life of patients.
Trial registration: The protocol for this study is registered with the Brazilian Registry of Clinical Trials (ReBEC RBR-7yhr4w
and World Health Organization under Universal Trial Number UTN: U1111-1127-9390 [http://www.ensaiosclinicos.gov.br/
rg/RBR-7yhr4w/]).
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Chronic kidney disease (CKD) is one of the most serious
public health problems. The increasing prevalence of
this disease in developed and developing countries has
led to a global epidemic. Current epidemiological sur-
veys suggest that approximately 1 million individuals
with terminal CKD have undergone kidney replacement
therapy worldwide. A large part of this epidemic may be
explained by the increase in the number of diabetes
mellitus cases and the increase in life expectancy. Dia-
betic nephropathy is expected to affect approximately
5.4% of the world population by 2015 [1].
CKD is defined as the presence of kidney damage
or reduced kidney function for ≥3 months, regardless
of the diagnosis. The advanced stage of this condition
is known as terminal CKD or end-stage kidney dis-
ease, with progressive and irreversible loss of kidney
function [2].
CKD is classified on the basis of the glomerular filtra-
tion rate (GFR), as recommended by the US National
Kidney Foundation Kidney Disease Outcomes Quality
Initiative, which provides the basis for the management
of this disease. CKD is classified into 5 stages: stage 1,
kidney damage with normal or increased GFR ≥ 90 mL/
(min⋅1.73 m2); stage 2, kidney damage with mildly de-
creased GFR of 60 to 89 mL/(min⋅1.73 m2); stage 3,
moderately decreased GFR of 30 to 59 mL/(min⋅1.73 m2);
stage 4, severely decreased GFR of 15 to 29 mL/
(min⋅1.73 m2); and stage 5, kidney failure with a GFR <
15 mL/(min⋅1.73 m2). Evidence of kidney damage
for ≥3 months is required for the diagnosis of stage 1 and 2
CKD, as manifested by pathological kidney abnormalities
or abnormal urine composition (such as haematuria or
proteinuria) or abnormalities on imaging tests [3].
The prevalence rate of sleep disorders in patients with
CKD ranges from 40% to 80%, which is higher than
those in the general population [4]. The most frequent
comorbidities include diabetes mellitus type 2 [1],periodic leg movements during sleep [4], obstructive sleep
apnea (OSA) and nocturnal hypoxemia [5], dyslipidaemia,
coronary disease, heart failure [6,7], systemic arterial hyper-
tension [8,9], respiratory disorders [10,11], stress[12 ], de-
pression [12-14], anxiety [15].
OSA is a respiratory disease characterised by the col-
lapse of the upper airways during sleep in predisposed
subjects. After chronic obstructive pulmonary disease
and asthma, OSA is the most important and wide-
spread respiratory disease, affecting 3% to 7% of the
male population and 2% to 5% of the female population
between 40 and 65 years of age in the Western world
[16]. In Brazil, the prevalence of OSA is even higher at
24.8% in men and 9.6% in women, according to a re-
cent epidemiological study conducted in the city of São
Paulo [17].
The causal association between OSA and CKD or
whether the 2 diseases result from a common patho-
physiologic process has not yet been clarified. Uremic
milieu has been implicated as a cause of OSA in patients
with CKD. Altered ventilatory drive and chemoreceptors
can lead to decreased respiration via a blunted response
to ventilatory stimuli, such as hypoxia or acidaemia.
Upper airway obstruction can occur from localised
oedema or the collapse of the dilator muscles, leading
to an increased risk of OSA. Suppression of the re-
spiratory musculature due to metabolic acidaemia/
acidosis, osmotic disequilibrium, and a reduction in
middle molecule clearance could potentially cause or
contribute to OSA [18].
Aims and hypotheses
The present study involving patients with CKD was
designed with 4 main objectives: (1) to assess the effects
of dialysis on sleep parameters and determine the preva-
lence and severity of sleep disorders; (2) to determine
the behaviour of sympathetic and parasympathetic auto-
nomic nervous system activity through an analysis of
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ibility as a risk indicator for OSA; and (4) to evaluate
levels of depression, anxiety, stress and quality of life.
Our hypothesis is that the weather weight gain due to
volume overload observed during interdialytic period
will influence the degree of collapsibility of the upper
airway due to narrowing and predispose to upper airway
occlusion during sleep, and to investigate the effects of
nocturnal hemodialysis compared to daytime hemodialysis
and the influences in the physiological variables of sleep,
autonomic nervous system (ANS), and respiratory mechan-
ics and thereby compromise the quality of life in chronic




A prospective, consecutive, double-blind, randomized
controlled clinical trial is proposed to investigate the ef-
fect of dialysis on sleep, pulmonary function, respiratory
mechanics, upper airway collapsibility, ANS, depression,
anxiety, stress and quality of life in end-stage renal dis-
ease patients, as summarised in Figure 1.
Subjects
The participants will be recruited from the Centro de
Nefrologia Zona Norte (São Paulo, Brazil) and sent to
the Sleep Laboratory of the Universidade Nove de Julho
(São Paulo, Brazil). Patients will be recruited consecu-
tively and screened for eligibility using a standardised
protocol. The following will be used as the inclusion
criteria: male or female patients aged 18 to 80 years;
chronic kidney failure; candidate for kidney transplant
with indication for dialysis; cognitive level sufficient for
understanding the procedures and following the instruc-
tions; and agreement to participate by signing a state-
ment of informed consent. Meanwhile, the following will
used as the exclusion criteria: craniofacial abnormalities;
undergoing active treatment of sleep apnea; active malig-
nancy; active alcohol and/or drug abuse; and dementia
or treatment-refractory psychiatric diseases leading to an
inability to provide informed consent.
Randomization
After the initial assessment and compliance with eligibility
criteria, participants will be randomized into two interven-
tion group [patients achieving diurnal hemodialysis and
nocturnal hemodialysis] and the control group [CKD not
submitted to dialysis]. Randomization numbers will be gen-
erated using a randomization table at a central office. A
series of numbered, sealed, opaque envelopes will be used
to ensure confidentiality. Each envelope will contain a card
stipulating to which group the subject will be allocated.Allpatients underwent randomization protocol that will meet
the eligibility criteria and be clinically stable.
Blinding
Baseline data will be collected prior to randomisation so
that trial investigators, assessors, research co-ordinators
and trial participants will be blinded to allocation while
the data is being collected. Blinding will be maintained
in all steps of the research.
Sample size calculation and statistical analysis
According to the findings of a previously published epi-
demiological study [17] that the proportion of adults
with an apnea/hypopnoea index (AHI) ≥ 15 corresponds
to 16.9% of the Brazilian population and that of a previ-
ous study [18] that AHI ≥ 15 had an approximately 50%
prevalence rate in patients with CKD undergoing con-
ventional dialysis (3 times a week, 4 h per session) [19],
the sample size was calculated as 57 patients, with an
α = 0.05 and β = 90% (test power).
The Kolmogorov–Smirnov normality test will first be
performed to determine whether a normal distribution
sample is present. A descriptive analysis will be
performed, with the data expressed as either mean and
standard deviation or median values and 95% confi-
dence intervals, as appropriate. One-way analysis of
variance will be used for comparisons between work
shifts once the samples have a normal distribution.
V0.2 and ΔV (%) values will be linearly correlated with
the AHI, for which either the Pearson or Spearman
correlation test will be used, depending on the sample
distribution. Either the non-paired Student t test or
Mann–Whitney test will be used for comparisons be-
tween individuals with and those without OSA.
In addition, a logistic regression analysis of continuous
factors with categorical responses will be performed.
Receiver operating characteristic (ROC) curves will be
constructed to determine the sensitivity (true-positive
rate) versus 100% specificity (false-positive rate) at vari-
ous levels of the measured Δ _V (%) and V0.2 (%) to iden-
tify the cut-off value yielding the largest number of
correctly classified patients. The statistical analysis will
be performed by an experienced statistician using the
JMP version 8.0 (SAS/STAT® Software, SAS Institute
Inc., Cary, NC, USA) and SPSS version 16.0 programs
(Somers NY). A 5% level of significance and 95% confi-
dence interval will be applied.
Ethical considerations
The study will be conducted in accordance with the eth-
ical standards established in the 1961 Declaration of
Helsinki (as revised in Hong Kong in 1989 and
Edinburgh, Scotland, in 2000) and is in compliance with
Figure 1 Flowchart of the study protocol.
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volving Human Subjects of the National Health Board of
the Brazilian Health Ministry issued in October 1996.
This protocol received approval from the Human Re-
search Ethics Committee of Universidade Nove de Julho
(Brazil) under process no. 368856/2010 and is registeredwith the World Health Organization under Universal
Trial Number (UTN) U1111-1127-9390 and the Brazil-
ian Registry of Clinical Trials (REBEC no. RBR-
7YHR4W). All participants will be required to sign a
statement of informed consent and will be allowed to
withdraw from the study at any time with no negative
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Patients with chronic kidney diseases and end-stage renal
disease undergoing dialysis, based on recommended proce-
dures, will be submitted to general physical measurements
performed by a well-trained physician and physical therap-
ist before and after the dialysis session using precise instru-
ments. The measurement protocol will include body weight
(kg); height (cm); body mass index (BMI) calculated using
the formula weight/height2 [16]; circumferences (cm) of the
neck, waist, and hip [20]; heart and respiratory rates; blood
pressures; Mallampati index [21]; tonsil index [22]; heart
rate variability [23]; maximum ventilatory pressure; negative
expiratory pressure (NEP) test; and polysomnography
(PSG; sleep study), as well as the administration of specific
questionnaires addressing sleep apnea, excessive daytime
sleepiness [24,25], symptoms of stress [12], and depression
[12-14], anxiety [15], and quality of life [26,27].
The following data will be obtained from medical charts:
biochemical values, associated pathological conditions, la-
boratory values (iron, intact-parathyroid hormone, haemo-
globin, calcium, phosphorus, and creatinine), duration of
dialysis therapy, comorbidities, and aetiology of kidney
disease.
Physical examination
Weight and height determinations will be performed
using an electronic scale (model 200/5; Welmy Industria
e Comercio Ltda, São Paulo, Brazil), and the BMI will be
calculated [16]. For the assessment of the tonsils and
Mallampati index scoring, each subject will be in the sit-
ting position and instructed to open the mouth as wide
as possible [21,22].
Waist and neck circumferences
Measurements of waist and neck circumferences will be
performed with a metric tape (7 mm in width). The sites
for the measurements will be standardised. Waist cir-
cumference will be measured at the midpoint between
the lower edge of the last rib and the iliac crest. Neck
circumference will be measured horizontally over the
cricoid cartilage [28].
Thorax and abdomen cirtometry
Cervical-thoracic abdominal cirtometry will be performed
to assess thorax and abdomen mobility and define the dia-
phragm index. The measurement will be performed by fix-
ing the zero point on the metric tape to the anterior region
of the thorax at the level that is being measured (axillary,
xiphoid, or abdominal), with the tape encircling the entire
circumference of the thorax or abdomen with maximalpossible pressure and the other extremity of the tape placed
over the same fixed point. The aim of applying the maximal
possible pressure of the tape on the body is to avoid the
interference of soft structures in the measurements.
Mobility and range of motion will be provided by maximal
inspiration and expiration [29].
Lung function tests
Spirometry
Lung function tests will be performed during the day,
with the patient seated in a comfortable position. For
such, the KoKo PFT Spirometer System version 4.11
(nSpire Health, Inc, Louisville, CO, USA) will be used in
accordance with the guidelines for the execution of lung
function tests established by the Brazilian Society of
Pneumology [30] and European Respiratory Society [31].
The subjects will perform the test in a comfortable pos-
ition, with the body erect and upper limbs unsupported.
All the examinations will be performed by a competent
technician trained in obtaining the necessary cooper-
ation from the subjects and appropriately operating the
equipment to ensure accurate, reproducible results. The
spirometer will be calibrated before each exam using a
3-L syringe [30].
Analysis of respiratory mechanics
Maximal inspiratory pressure and maximal expiratory
pressure physiologically constitute the most adequate
test for the determination of ventilatory muscle strength.
Maximal inspiratory pressure is an indicator of ventila-
tory capacity and the development of respiratory failure,
the measurement of which is indicated for the assess-
ment of the degree of abnormality and monitoring of
the weakening of individual inspiratory muscles in dis-
ease progression [32]. The tests will be performed on
the same day on which the patients will undergo spirom-
etry. The tests will be performed in a quiet setting. The
patients will be seated comfortably, breathing calmly and




The Berlin questionnaire is used to identify patients at
high risk of respiratory sleep disorders in a variety of
populations. This clinical history questionnaire has
recognised efficacy in distinguishing individuals at high
risk of OSA, with 10 items organised into 3 categories as
follows: snoring and apnea (5 items), daytime sleepiness
(4 items), and systemic arterial hypertension and obesity
(1 item). All marked responses are considered positive.
The score is divided into the following categories: cat-
egory 1 is considered positive in the occurrence of 2 or
more positive responses to items 1 to 5; category 2, in
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6 to 8; and category 3, when the response to item 9 is
“yes” or when the BMI ≥ 30 kg/m2. Two or more positive
categories indicate a high risk of OSA [24].
Epworth Sleepiness Scale
The Epworth Sleepiness Scale is a simple, self-administered
questionnaire with items addressing situations involving
activities of daily living and the occurrence of daytime
sleepiness in adults. The subjects will be instructed to clas-
sify their likelihood of feeling the desire to nap or sleep in 8
situations on a scale of 0 to 3 (0, no chance of napping; 1,
small chance of napping; 2, moderate chance of napping;
and 3, strong chance of napping) [25,33].
Polysomnography
All the patients will undergo a standard overnight PSG
(Embla, A10 version 3.1.2 Flaga, Hs. Medical Devices,
Reykjavik, Iceland) at the Sleep Laboratory of Nove de
Julho University. Polysomnography exams will be held
the night before the haemodialysis and approximately
12 hours after this dialysis. All recording sensors will be
attached to the patient in a non-invasive manner using
tape or elastic bands. The following physiological vari-
ables will be monitored simultaneously and continu-
ously: 4 channels for the electroencephalogram (C3-A2,
C4-A1, O1-A2, and O2-A1), 2 channels for the electro-
oculogram (EOG-Left-A2 and EOG-Right-A1), 4 chan-
nels for the surface electromyogram (muscles of the
submentonian region, anterior tibialis muscle, masseter
region, and seventh intercostal space), electrocardio-
gram (derivation V1 modified), airflow detection via 2
channels through a thermocouple and nasal pressureFigure 2 Schematic representation of the negative expiratory pressurcannula, respiratory effort of the thorax and abdomen
via x-trace belts, snoring and body position sensors,
and arterial oxygen saturation and pulse rate via an
oximeter.
All the subjects will be monitored by a technician ex-
perienced in PSG. Sleep stages will be visually scored in
30-s epochs, and each PSG recording will be analysed
manually under blinded conditions by the same exam-
iner with experience in scoring PSG recordings in ac-
cordance with international standards established by the
Academy of Sleep Medicine Manual for Scoring Sleep
and Associated Events. The patients will be instructed to
remain as relaxed as possible and sleep naturally, as if at
home. All signals will be recorded continuously [34,35].
NEP test
The NEP test will be conducted before and after
hemodialysis sessions, performed through the adminis-
tration of a negative pressure at the mouth during expir-
ation. This is a practical test performed while awake and
requires little cooperation from the subject. In the ab-
sence of expiratory flow limitation, the increase in the 8
pressure gradients between the alveoli and the open
upper airway caused by NEP results in an increase in ex-
piratory flow.
NEP will be generated by the Super Air Amplifier
(Exair model 120021, Cincinnati, OH, USA) coupled to
a tank of compressed air via an electrically operated so-
lenoid valve (model 95004, Norgren Ltd; Vimercate, MI,
Italy) automatically activated in early expiration and kept
open for 2 s by software control (Figure 2). A pneumo-
tachograph (Hans Rudolph model 3830; Kansas, MO,
USA) will be connected to the air amplifier and thee.
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ducers (PCLA02X5; Sensortechnics GmbH, Puchheim,
Germany). Mouth pressure will be measured by pressure
transducers (PCLA0050; Sensortechnics GmbH, Puchheim,
Germany). NEP of 10-cm H2O will be set by occluding the
pneumotachograph with a stopper and adjusting the flow
of compressed air-to-air amplifier (Figure 2).
Each NEP manoeuvre will be performed each after at
least 4 breaths to normalise the breathing pattern. The
tests will be performed once with the subject seated
comfortably and again in supine position on a cot. In
both positions, care will be taken to maintain the com-
fort of the subjects, with the neck in a neutral position,
as it has been documented that the position of the head
exerts an influence on upper airway collapsibility [36].
All manoeuvres will be performed with the subjects
awake and wearing a nose clip. The airflow and mouth
pressure signals will be low-pass filtered and sampled at
200 Hz. Both digital signals will be displayed in real time
on the monitor and stored on the computer for subse-
quent analysis. Signal analysis and solenoid valve control
will be performed using software written in 9 LabVIEW
8.2 (National Instruments) developed by the Italian Na-
tional Research Council, Institute of Biomedicine and
Molecular Immunology “A. Monroy.”
NEP application during tidal expiration produces an
immediate peak flow followed by a sudden drop of a
variable degree. Upper airway collapsibility is to be eval-
uated by measuring flow limitation as flow drop (Δ _V )
expressed as the percentage of peak flow immediately
after NEP administration. To avoid reflex and volun-
tary reactions to the NEP stimulus, the minimum
flow will be identified in the first 200 ms of NEP
administration [37].
Upper airway collapsibility will also evaluated by meas-
uring V0.2 immediately after NEP administration. These
values will be expressed as the percentage of mean in-
spiratory volume of the 3 breaths preceding NEP admin-
istration. Measured volumes will be accepted only when
differences between inspiration and expiration for each
of the 3 previous breaths are less than 10%. Values of
V0.2 and Δ _V (%) are calculated as the mean of 4 mea-
surements. Measurements of upper airway collapsibility
will be evaluated as expiratory volume in 0.2 s (percent-
age of the mean inspiratory volume of the 3 breaths
preceding NEP application) and as flow drop ( Δ _V ),
expressed as the percentage of peak flow.Assessment of ANS
Nerve-Express is a fully automatic, non-invasive
computer-based system designed for the quantitative
assessment of the ANS on the basis of the analysis of
heart rate variability. This system is based on a methodof clusterisation of the relationship between sympa-
thetic and parasympathetic nervous system statuses.
This technological breakthrough is achieved by using
proprietary algorithms and a new approach based on
a leading theory of artificial intelligence, the Marvin
Minsky’s Frame Theory. Nerve-Express provides an ob-
jective and reliable real-time evaluation of the ANS state
during the orthostatic test and Valsalva manoeuvre
combined with deep breathing.
A signal sensor is attached to the thorax by an elastic
strap and is coupled to the Nerve-Express software pro-
gram, which collects and stores the data. The modality
of the exam is the orthostatic test, in which the patient
goes from the supine to the orthostatic position [38,39].
Inventory of symptoms of stress for adults
The Inventory of Symptoms of Stress for Adults (LIPP)
is based on a 4-phase model of stress and its manifesta-
tions in the somatic and cognitive domains. In the initial
stress phase, which is called the alert phase, the body
makes greater efforts to prepare itself to cope with a
stressor. This phase is considered a positive phase of
stress because it is important for adjustments to envir-
onmental demands.
The second phase is called resistance and occurs when
a chronic stressor demands coping for a long period of
time. This phase is associated with fatigue, perception of
burnout, and cognitive loss. The next phases, referred to
as almost exhaustion and exhaustion, are consequences
of the breakdown of resistance and loss of capacity for
adjustment. During these phases, one can observe im-
portant changes in sleep, work, and libido in addition to
symptoms of anxiety and depression [12].
Hamilton anxiety rating scale (HAM-A)
The term depression is used to describe a clinical syn-
drome, where there are several particular signs and
symptoms. Depression can occur as a primary manifest-
ation of mood, associated with systemic medical ill-
nesses, other psychiatric disorders or disorders arising
from the use of psychoactive substances. With regard to
the study of depression, has not, to date, the biological
or physiological parameters to evaluate its clinical mani-
festations in a definitive or conclusive. So the depression
scales emerge as useful tools for assessing the severity of
depressive, serving to translate clinical phenomenon in
objective and quantitative information. In addition to
characterizing the intensity of depression, these scales
would serve to evaluate the response to treatment when
applied before, during and after therapeutic intervention.
Within this context, the rating scales of depression se-
verity, whose first date from the end of the last century
can be divided into ranges: a) self-assessment, b) hetero
c) mixed, involving self and observer.[15]
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an observer, was the Hamilton Rating Scale for Depres-
sion (HAM-D), designed and developed by Hamilton in
the late 50s. Currently, it is the most widely used depres-
sion scale worldwide and is probably the most important
being regarded as “standard gold” in assessing the sever-
ity of depression compared with new and used rating
scales in order to check the reliability of these.
Rating Scale Hamilton Anxiety is one of the most
atualemnte used to assess anxiety in patients and is
composed of 14 items (6 items - Humor anxious and 8
items - Physical symptoms) that pertain to the observed
behavior. The patient will respond from their own ex-
perience the classification of symptoms present in Likert
scale where 0 = absent, 1 = mild, 2 =medium intensity,
3 = 4 = strong intensity and moderate intensity.
The total score reflects the general state of the pa-
tient’s anxiety, the aspects considered by the scale for
the assessment are: mood, cognition, behavior, alertness
and somatic symptoms, and in addition to other symp-
toms, scores between 0 and 17 are considered normal,
between 18:25 26 moderate and 30 severe, over 30 are
uncommon, but show a severe state of anxiety [40,41].
Beck depression inventory
The Beck Depression Inventory (BDI) has 21 items, in-
cluding attitude, depressive symptoms, and suicidal idea-
tion, scored on a scale ranging from 0 to 3. The cut-off
scores are as follows: <11, minimal depression; 12 to 19,
mild to moderate depression; 20 to 35, moderate depres-
sion; and 36 to 63, severe depression [12].
Quality of life
Patients with CKD may develop eating disorders due to
the diet and water intake restrictions during treatment,
which may also result in dysfunctional behaviour and
treatment noncompliance. Thus, stress, anxiety, and de-
pression are common among such patients and imply a
reduction in quality of life. The Short Form 36 (SF-36)
will be used for the assessment of quality of life. This
measure has 36 questions grouped into 8 domains or
scales of physical functioning, role limitations due to
physical health, bodily pain, general health perception,
social functioning, and role limitations due to emotional
problems, vitality, and mental health [26,27].
Study interventions
Haemodialysis
Regular daytime or nocturnal haemodialysis was
standardised during the trial. It was performed 3 times
per week, with a 4-h session duration, 250-mL/min blood
flow, and 500-mL/min dialysate flow, using bicarbonate-
buffered dialysate with 1.25 mmol/L ionised calciumconcentration, dialysate temperature of 36.5°C, and Polyflux
17-L dialyser [42].
The ultrafiltration amount for each haemodialysis session
was decided by individual dry weight, which was fixed dur-
ing the trial. In addition, during the trial, the patients were
not permitted to change their medication or start new
drugs, especially antiplatelet agents, angiotensin-converting
enzyme inhibitors, angiotensin II receptor antagonists,
calcium-channel blockers, and β-blockers.
The patients who required a change in medication for
medical reasons were subsequently excluded from the
study. Use of N-acetylcysteine was also prohibited in
view of its potential influence on ischemia-reperfusion
injury.Quality control
To ensure the quality of the data, the physiotherapists
and physicians in charge of data collection will receive
specific training. Periodic external monitoring will be
performed to verify the adequate application of method-
ology in performing examinations and data collection.Discussion
CKD is a major public health problem worldwide, and
its incidence has increased in part by the increased life
expectancy and increasing number of cases of diabetes
mellitus and hypertension. Sleep disorders are common
in patients with renal insufficiency and is much more
prevalent in patients with end-stage renal disease than
in the general population [4].
Symptomatic obstructive sleep apnoea syndrome has
been related to be a risk factor for hypertension, heart
failure and vascular dysfunction, and has been proposed
to be causally related to both non-fatal and fatal coron-
ary and cerebrovascular events [43]. Moreover, renal
chronic patients frequently presented restless legs syn-
drome that also is associated with higher mortality and
elevated incidence of cardiovascular events [44]. Thus,
once presence of OSA also seems to reduce quality of
haemodialysis [45] it’s incorrectly identification among
CKD patients may lead to worst outcomes or fail of
hypertension control [46].
Our hypothesis is that the weather weight gain due to
volume overload observed during interdialytic period
will influence the degree of collapsibility of the upper
airway due to narrowing and predispose to upper airway
occlusion during sleep, and to investigate the influences
of different shifts haemodialysis in the physiological vari-
ables of sleep and ANS activity, and respiratory mechan-
ics, and depression, anxiety, stress and quality of life in
end-stage renal disease patients. With our proposed
study, we intend to identify the main factors that cause
sleep disorders in patients with CKD that lead to the
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and improve the quality of life of these patients.
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